Download PDF
Zeitschrift für Orthomolekulare Medizin 2009; 7(2): 11-15
DOI: 10.1055/s-0029-1185643
Wissen

© Hippokrates Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Resveratrol und seine Bedeutung für die Anti-Aging-Medizin

Bernd Kleine-Gunk
Further Information

Publication History

Publication Date:
12 June 2009 (online)

    Permissions and Reprints

Zusammenfassung

Resveratrol ist ein potentes Antioxidans, das auch antiinflammatorische und chemopräventive Wirkungen aufweist. Darüber hinaus besitzt es eine Eigenschaft, die vor allem für die Anti-Aging-Medizin von größter Bedeutung ist: Resveratrol täuscht dem Körper eine Kalorienrestriktion vor, von der man weiß, dass sie bis heute die einzige experimentell belegte Methode zur Lebensverlängerung ist.

Schlüsselwörter

Resveratrol - Rotwein - Antioxidans - CR‐Mimetika

Literatur

  • 1 Aggarwal B B, Bhardwaj A, Aggarwal R S, Seeram N P, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies.  Anticancer Res. 2004;  24 2783-2840
    Google Scholar
  • 2 Anderson R M, Bittermann K J, Wood J G, Medvedik O, Sinclair D A. Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae.  Nature. 2003;  423 181-185
    CrossrefGoogle Scholar
  • 3 Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration.  Science. 2004;  305 1010-1013
    CrossrefGoogle Scholar
  • 4 Criqui M H, Ringel B L. Does diet or alcohol explain the French paradox?.  Lancet. 1994;  344 1719-1723
    CrossrefGoogle Scholar
  • 5 Crowell J A, Korytko P J, Morrisey R L, Levine B S. Resveratrol-associated renal toxicity.  Toxicol Sci. 2004;  82 614-619
    CrossrefGoogle Scholar
  • 6 Dorrie J C, Gerauer H, Wachter Y, Zunino S J. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukaemia cells.  Cancer Res. 2001;  61 4731-4739
    Google Scholar
  • 7 Frankel E N, Waterhouse A L, Kinsella J E. Inhibition of human LDL oxidation by resveratrol.  Lancet. 1993;  341 1103-1104
    PubMedGoogle Scholar
  • 8 Fulda S, Debatin K M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol.  Cancer Res. 2004;  64 337-346
    CrossrefGoogle Scholar
  • 9 Gronbaek M, Deis A, Sorensen T IA, Becker U, Schnohr P, Jensen G. Mortality associated with moderate intakes of wine, beer, or spirits.  BMJ. 1995;  310 1165-1169
    Google Scholar
  • 10 Howitz K T, Bitterman K J, Cohen H Y, Lamming D W, Lavu S, Wood J G, Zipkin R E, Chung P, Kisielewski A, Zhang L L, Scherer B, Sinclair D A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan.  Nature. 2003;  425 191-196
    CrossrefPubMedGoogle Scholar
  • 11 Hung L M, Chen J K, Huang S S, Lee R S, Su M J. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes.  Cardiovasc Res. 2000;  47 549-555
    CrossrefGoogle Scholar
  • 12 Ignatowicz E, Baer-Dubowska W. Resveratrol, a natural chemopreventive agent against degenerative diseases.  Pol J Pharmacol. 2001;  53 557-569
    Google Scholar
  • 13 Jang M S, Cai E N, Udeani G O, Slowing K V, Thomas C F. et al . Cancer chemopreventive activity of resveratrol, a natural product derived from grapes.  Science. 2002;  275 218-220
    Google Scholar
  • 14 Baur J A, Pearson K J, Price N L. et al . Resveratrol improves health and survival of mice on a high-calorie diet.  Nature. 2006;  444 337-342
    CrossrefPubMedGoogle Scholar
  • 15 Kevin S. Gould, nature's swiss army knife: the diverse protective roles of Anthocyanins in leaves.  J Biomed Biotechnol. 2004;  5 314-320
    Google Scholar
  • 16 Klatsky A L, Armstrong M A, Friedman G D. Red wine, white wine, liquor, beer and risk for coronary artery disease hospitalization.  Am J Cardiol. 1997;  80 416-420
    CrossrefGoogle Scholar
  • 17 Kundu J K, Surh Y-J. Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP‐1 as potential targets.  Mutat Res. 2004;  555 65-80
    CrossrefPubMedGoogle Scholar
  • 18 Langley E, Pearson M, Faretta M, Bauer U M, Frye R A, Minucci S, Pelicci P G, Kouzarides T. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence.  EMBO J. 2002;  21 2383-2396
    CrossrefGoogle Scholar
  • 19 Leonard S, Xia C, Jiang B H, Stinefelt B, Klandorf H, Harris G K, Shi X. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses.  Biochem Biophys Res Commun. 2003;  309 1017-1026
    CrossrefGoogle Scholar
  • 20 Lin S J, Defossez P A, Guarente L. Requirement of NAD and SIR 2 for lifespan extension by calorie restriction in Saccharomyces cerevisiae.  Science. 2000;  289 2126-2128
    CrossrefGoogle Scholar
  • 21 Mahyar-Roemer M, Kohler H, Roemer K. Role of Bax in resveratrol-induced apoptosis of colorectal carcinoma cells.  BMC Cancer. 2002;  2 27-36
    CrossrefGoogle Scholar
  • 22 Martinez J, Moreno J J. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production.  Biochem Pharmacol. 2000;  59 865-870
    CrossrefGoogle Scholar
  • 23 Marx J. Cancer research. Inflammation and cancer: the link grows stronger.  Science. 2004;  306 966-968
    CrossrefGoogle Scholar
  • 24 McCay C M, Cromwell M F, Maynard L A. The effect of retarded growth upon the length of life span upon the ultimate body size.  J Nutr. 1935;  10 63-79
    Google Scholar
  • 25 McGeer E G, McGeer P L. Inflammatory processes in Alzheimer's disease.  Prog Neuropsychopharmacol Biol Psychiatry. 2003;  27 741-749
    CrossrefGoogle Scholar
  • 26 Mertens-Talcott S U, Percival S S. Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause translent cell cycle arrest in human leukemia cells.  Cancer Lett. 2005;  218 141-152
    CrossrefPubMedGoogle Scholar
  • 27 Olas B, Zbikowska H M, Wachowicz B, Krajewski A, Magnuszewska A. Inhibitory effect of resveratrol on free radical generation in blood platelets.  Acta Biochem Pol. 1999;  46 961-966
    Google Scholar
  • 28 Pervaiz S. Reveratrol. From grapevines to mammalian biology.  FASEB J. 2003;  17 1975-1985
    CrossrefGoogle Scholar
  • 29 Philip M, Rowley D A, Schreiber H. Inflammation as a tumor promoter in cancer induction.  Semin Cancer Biol. 2004;  14 433-439
    CrossrefPubMedGoogle Scholar
  • 30 Renaud S, de Lorgeril M. Wine, alcohol, platelets and the French paradox for coronary heart disease.  Lancet. 1992;  339 1523-1526
    CrossrefGoogle Scholar
  • 31 Savaskan E, Olivieri G, Meier F, Seifritz E, Wirz-Justice A, Muller-Spahn F. Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity.  Gerontology. 2003;  49 380-383
    CrossrefGoogle Scholar
  • 32 Steinberg D, Parthasarathy S, Carew T E, Khoo J C, Witzthum J L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.  N Engl J Med. 1989;  320 915-924
    CrossrefPubMedGoogle Scholar
  • 33 Subbaramaiah K, Michaluart P, Chung W J, Tanabe T, Telang N, Dannenberg A J. Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells.  Ann NY Acad Sci. 1999;  889 214-223
    CrossrefGoogle Scholar
  • 34 Tsai S H, Lin-Shiau S Y, Lin J K. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol.  Br J Pharmacol. 1999;  126 673-680
    CrossrefGoogle Scholar
  • 35 Virgili M, Contestabile A. Partial neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats.  Neurosci Lett. 2000;  281 123-126
    CrossrefGoogle Scholar
  • 36 Walle T, Hsieh F, DeLegge M H. et al . High absorption but very low bioavailability of oral resveratrol in humans.  Drug Metab Dispos. 2004;  32 1377-1382
    CrossrefGoogle Scholar
  • 37 Willerson J T, Ridker P M. Inflammation as a cardiovascular risk factor.  Circulation. 2004;  109 II2-II10
    CrossrefGoogle Scholar
  • 38 Wood J G, Rogina B, Lavu S, Howitz S L, Helfland S L, Tatar M, Sinclair D. Sirtuin activators mimic calorie restriction and delay ageing in metazoans.  Nature. 2004;  430 686-689
    CrossrefGoogle Scholar

Dr. med. Bernd Kleine-Gunk

EuromedClinic

Europaallee 1

90763 Fürth

Email: kleine-gunk@euromed.de